Roflumilast, a type of phosphodiesterase 4 inhibitor, can reduce intestinal injury caused by sepsis

Zhang,Zhongyuan; Liang,Meifeng; Wan,Xiongfei

doi:10.3892/etm.2021.10834

Roflumilast, a type of phosphodiesterase 4 inhibitor, can reduce intestinal injury caused by sepsis

Authors:
- Zhongyuan Zhang
- Meifeng Liang
- Xiongfei Wan
View Affiliations

Affiliations: Department of Pharmacy, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430060, P.R. China, Department of Medical Insurance and Management, CR & WISCO General Hospital, Wuhan, Hubei 430000, P.R. China, Department of Pharmacy, CR & WISCO General Hospital, Wuhan, Hubei 430000, P.R. China
Published online on: October 1, 2021 https://doi.org/10.3892/etm.2021.10834
Article Number: 1398
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sepsis is a systemic inflammatory response syndrome caused by infection, which has a complex mechanism. The gastrointestinal tract is commonly the first organ affected by sepsis, but intestinal disease itself can also induce sepsis. Roflumilast has been found to exert anti‑inflammatory effects and, thus, the present study sought to examine its effect on intestinal damage caused by sepsis. In vivo studies were conducted using cecal ligation and puncture rat models, and in vitro experiments were performed using IEC‑6 cells. The intestinal cells were first induced with lipopolysaccharide and the induced cells were then treated with roflumilast to evaluate its effects on phosphodiesterase (PDE)4 expression, intestinal function indices, release of inflammatory factors and cell apoptosis. The expression level of PDE4 in the small intestinal tissue of septic rats was found to be significantly higher compared with that in the normal group, suggesting that PDE4 may play a key role in intestinal injury caused by sepsis. It was found that roflumilast reduced PDE4 expression, as well as the levels of intestinal function indices, including lactate dehydrogenase, diamino oxidase and intestinal fatty acid‑binding protein, in intestinal cells. Moreover, roflumilast reduced cellular damage, the release of inflammatory factors and apoptosis. In summary, the findings of the present study indicated that roflumilast can relieve the inflammation and apoptosis of intestinal cells caused by sepsis and can promote their functional recovery. These findings may promote the expansion of the clinical application of roflumilast in the future.

View Figures

View References

1	Faix JD: Biomarkers of sepsis. Crit Rev Clin Lab Sci. 50:23–36. 2013.PubMed/NCBI View Article : Google Scholar
2	Huang M, Cai S and Su J: The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci. 20(5376)2019.PubMed/NCBI View Article : Google Scholar
3	Martin GS: Sepsis, severe sepsis and septic shock: Changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 10:701–706. 2012.PubMed/NCBI View Article : Google Scholar
4	Rossaint J and Zarbock A: Pathogenesis of multiple organ failure in sepsis. Crit Rev Immunol. 35:277–291. 2015.PubMed/NCBI View Article : Google Scholar
5	Huang CT, Tsai YJ, Tsai PR, Yu CJ and Ko WJ: Epidemiology and outcome of severe sepsis and septic shock in surgical intensive care units in Northern Taiwan. Medicine (Baltimore). 94(e2136)2015.PubMed/NCBI View Article : Google Scholar
6	Martinez A and Gil C: cAMP-specific phosphodiesterase inhibitors: Promising drugs for inflammatory and neurological diseases. Expert Opin Ther Pat. 24:1311–1321. 2014.PubMed/NCBI View Article : Google Scholar
7	Lynch MJ, Hill EV and Houslay MD: Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. Curr Top Dev Biol. 75:225–259. 2006.PubMed/NCBI View Article : Google Scholar
8	Ioakeimidis N and Kostis JB: Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. J Cardiovasc Pharmacol Ther. 19:53–64. 2014.PubMed/NCBI View Article : Google Scholar
9	Peng T, Qi B, He J, Ke H and Shi J: Advances in the development of phosphodiesterase-4 inhibitors. J Med Chem. 63:10594–10617. 2020.PubMed/NCBI View Article : Google Scholar
10	Di Luigi L, Sansone M, Sansone A, Ceci R, Duranti G, Borrione P, Crescioli C, Sgrò P and Sabatini S: Phosphodiesterase type 5 inhibitors, sport and doping. Curr Sports Med Rep. 16:443–447. 2017.PubMed/NCBI View Article : Google Scholar
11	Xu M, Yu X, Meng X, Huang S, Zhang Y, Zhang A and Jia Z: Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 318:F576–F588. 2020.PubMed/NCBI View Article : Google Scholar
12	Sakkas LI, Mavropoulos A and Bogdanos DP: Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of action, clinical applications, current and future perspectives. Curr Med Chem. 24:3054–3067. 2017.PubMed/NCBI View Article : Google Scholar
13	Myers SA, Gobejishvili L, Saraswat Ohri S, Garrett Wilson C, Andres KR, Riegler AS, Donde H, Joshi-Barve S, Barve S and Whittemore SR: Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia. Neurobiol Dis. 124:353–363. 2019.PubMed/NCBI View Article : Google Scholar
14	Feng H, Chen J, Wang H, Cheng Y, Zou Z, Zhong Q and Xu J: Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice. Lab Invest. 97:1008–1019. 2017.PubMed/NCBI View Article : Google Scholar
15	Chang X, Hu LF, Ma XJ, Yin J, Liu XY and Li JB: Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway. Eur Rev Med Pharmacol Sci. 23:1335–1341. 2019.PubMed/NCBI View Article : Google Scholar
16	Xu X, Liao L, Hu B, Jiang H and Tan M: Roflumilast, a phosphodiesterases-4 (PDE4) inhibitor, alleviates sepsis-induced acute kidney injury. Med Sci Monit. 26(e921319)2020.PubMed/NCBI View Article : Google Scholar
17	El-Ashmawy NE, Khedr NF, El-Bahrawy HA and El-Adawy SA: Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP. Int Immunopharmacol. 56:36–42. 2018.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Stoller J, Halpin L, Weis M, Aplin B, Qu W, Georgescu C and Nazzal M: Epidemiology of severe sepsis: 2008-2012. J Crit Care. 31:58–62. 2016.PubMed/NCBI View Article : Google Scholar
20	Sertaridou E, Papaioannou V, Kolios G and Pneumatikos I: Gut failure in critical care: Old school versus new school. Ann Gastroenterol. 28:309–322. 2015.PubMed/NCBI
21	Yang H, Song Z, Jin H, Cui Y, Hou M and Gao Y: Protective effect of rhBNP on intestinal injury in the canine models of sepsis. Int Immunopharmacol. 19:262–266. 2014.PubMed/NCBI View Article : Google Scholar
22	Deitch EA: Bacterial translocation or lymphatic drainage of toxic products from the gut: What is important in human beings? Surgery. 131:241–244. 2002.PubMed/NCBI View Article : Google Scholar
23	Deitch EA, Xu D and Kaise VL: Role of the gut in the development of injury- and shock induced SIRS and MODS: The gut-lymph hypothesis, a review. Front Biosci. 11:520–528. 2006.PubMed/NCBI View Article : Google Scholar
24	Li H, Fan C, Feng C, Wu Y, Lu H, He P, Yang X, Zhu F, Qi Q, Gao Y, et al: Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. Br J Pharmacol. 176:2209–2226. 2019.PubMed/NCBI View Article : Google Scholar
25	Kumar P, Nagarajan A and Uchil PD: Analysis of cell viability by the lactate dehydrogenase assay. Cold Spring Harb Protoc. 2018:2018.PubMed/NCBI View Article : Google Scholar
26	Wolvekamp MC and de Bruin RW: Diamine oxidase: An overview of historical, biochemical and functional aspects. Dig Dis. 12:2–14. 1994.PubMed/NCBI View Article : Google Scholar
27	Derikx JP, Schellekens DH and Acosta S: Serological markers for human intestinal ischemia: A systematic review. Best Pract Res Clin Gastroenterol. 31:69–74. 2017.PubMed/NCBI View Article : Google Scholar
28	Sakai M, Suzuki T, Tomita K, Yamashita S, Palikhe S, Hattori K, Yoshimura N, Matsuda N and Hattori Y: Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: Attribution to phosphodiesterase 4 upregulation. Am J Physiol Heart Circ Physiol. 312:H1224–H1237. 2017.PubMed/NCBI View Article : Google Scholar
29	Gong S, Chen Y, Meng F, Zhang Y, Li C, Zhang G, Huan W and Wu F: Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis. Cell Prolif. 51(e12474)2018.PubMed/NCBI View Article : Google Scholar
30	Takano A, Uz T, Garcia-Segovia J, Tsai M, Lahu G, Amini N, Nakao R, Jia Z and Halldin C: A nonhuman primate PET study: Measurement of brain PDE4 occupancy by roflumilast using (R)-[¹¹C]Rolipram. Mol Imaging Biol. 20:615–622. 2018.PubMed/NCBI View Article : Google Scholar
31	Peng S, Yan HZ, Liu PR, Shi XW, Liu CL, Liu Q and Zhang Y: Phosphodiesterase 4 inhibitor roflumilast protects rat hippocampal neurons from sevoflurane induced injury via modulation of MEK/ERK signaling pathway. Cell Physiol Biochem. 45:2329–2337. 2018.PubMed/NCBI View Article : Google Scholar